Workflow
浙江昂利康制药股份有限公司关于回购公司股份的进展公告

Core Viewpoint - The company has approved a share repurchase plan to buy back a portion of its publicly issued shares using its own funds and a special loan, with a total repurchase amount between RMB 50 million and RMB 70 million, and a maximum price of RMB 21.07 per share [1] Group 1: Share Repurchase Plan - The company plans to use its own funds and a special loan to repurchase shares, with a total amount not less than RMB 50 million and not exceeding RMB 70 million [1] - The repurchase price will not exceed RMB 21.07 per share, and the actual number of shares repurchased will depend on the execution [1] - The implementation period for the repurchase is set for up to 12 months from the board's approval date [1] Group 2: Progress of Repurchase - As of July 31, 2025, the company has repurchased a total of 3,599,700 shares, accounting for approximately 1.78% of the total share capital [2] - The highest transaction price during the repurchase was RMB 17.00 per share, while the lowest was RMB 12.17 per share, with a total transaction amount of RMB 50,001,275.28 (excluding transaction fees) [2] Group 3: Compliance and Regulations - The company has adhered to the regulations set forth by the Shenzhen Stock Exchange regarding share repurchase, including not repurchasing during significant events that could impact share prices [3] - The repurchase transactions comply with the requirements that the entrusted price must not exceed the daily trading limit and must not occur during specific trading periods [3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [3]